Print（PDF/181KB） Oct. 30, 2024 Corporate
Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignment and changes in Executive Officers and other key positions, effective December 1, 2024, as part of fundamental business structural reform.
Ⅰ. Organizational Realignment (effective December 1, 2024)
Corporate Departments
Related functional departments are integrated and reorganized into a lean and efficient organization.
- 1.Part of function of Global Corporate Strategy is transferred to newly created R&D Strategy and Planning under Research and Development Division.
- 2.IT Management & Data Analytics is created by integrating Global Data Design Office and IT Management & Digital Transformation.
- 3.Regulatory Affairs is transferred to under Corporate Regulatory Compliance & Quality Assurance Division.
- 4.Corporate Secretariat is dissolved and its functions are transferred to External Affairs.
- 5.Part of function of Corporate Governance is transferred to Legal Affairs and Legal Affairs is renamed to Legal & Compliance.
- 6.Corporate Communications is dissolved and its functions are transferred to Global Finance and Corporate Governance.
- 7.Medical Science is dissolved and its functions are transferred to Regulatory Affairs under Corporate Regulatory Compliance & Quality Assurance Division and newly created Medical Affairs under Research and Development Division.
Corporate Regulatory Compliance & Quality Assurance
(Division)
Regulatory Compliance & Quality Assurance Management is renamed (in Japanese language
only).
Research and Development (Division) (Currently, Drug Research Division, Drug
Development
Division, and Technology Research & Development Division)
Drug Research Division, Drug Development
Division, and Technology Research & Development
Division are integrated and reorganized into a lean organization to promote R&D activities under a unified
activity strategy.
- 1.Research and Development Division is created by integrating Drug Research Division, Drug Development Division, and Technology Research & Development Division.
- 2.R&D Strategy and Planning is created by integrating part of function of Research Planning & Coordination, Development Planning & Management, and Technology Research & Development Management, and External Innovation.
- 3.R&D Management is created by integrating part of function of Research Planning & Coordination, Development Planning & Management, and Technology Research & Development Management.
- 4.CNS Drug Discovery Research Unit is created by integrating part of function of Pharmacology Research Unit and Platform Technology Research Unit.
- 5.Modality Research Unit is dissolved and its functions are transferred to Cancer Drug Discovery Research Unit.
- 6.Drug Discovery Digital Innovation Unit is created by integrating part of function of Research Planning & Coordination, Platform Technology Research Unit, and Technology Research & Development Management.
- 7.Part of function of Development Planning & Management is transferred to Clinical Operation.
- 8.Process Research & Development Laboratories is renamed to Process R&D Unit.
- 9.Formulation Research & Development Laboratories is renamed to Formulation R&D Unit.
- 10. Analytical Research & Development Laboratories is renamed to Analytical R&D Unit.
- 11. Medical Affairs is created.
Research Planning & Coordination, Development Planning & Management,
Technology
Research & Development Management, and Platform Technology Research Unit are dissolved by
integrating and
transferring their functions to newly created departments.
Sales & Marketing (Division)
Division’s functions and branches are
integrated for efficient organization and productivity
improvement.
- 1.MarTech Strategy Office and Personnel Development are dissolved and their functions are transferred to Sales & Marketing Management.
- 2.Product Marketing is created by integrating part of function of Sales & Marketing Management and Rare Diseases Office, Product Marketing, and CNS Product Marketing.
- 3.Distribution Management is renamed to Distribution Policy Management.
- 4.Hokkaido-Tohoku Branch is created by integrating Sapporo Branch and Tohoku Branch.
- 5.Kanto-Koshinetsu Branch is created by integrating Kita-Kanto-Koshinetsu Branch and part of Saitama-Chiba Branch.
- 6.Shutoken Branch is created by integrating part of Saitama-Chiba Branch, Tokyo Branch, and Yokohama Branch.
- 7.Tokai-Hokuriku Branch is created by integrating Tokai Branch and part of Keiji-Hokuriku Branch.
- 8.Kansai Branch is created by integrating by part of Keiji-Hokuriku Branch and Osaka Branch.
- 9.Chugoku-Shikoku Branch is created by integrating Chugoku Branch and Shikoku Branch.
Supply Chain (Division)
- 1.Manufacturing Division is renamed to Supply Chain Division.
- 2.Manufacturing Management is renamed to Supply Chain Management.
Ⅱ. Changes in Executive Officers
(1) Promotion (effective December 1, 2024)
-
Managing Executive Officer
Yumi Sato (currently Executive Officer)
(2) New Executive Officers (effective December 1, 2024)
- Koji Yamazaki (currently Sales & Marketing Division, Senior Vice President, Head of Sales & Marketing Division)
- Kimihiro Mizuno (currently Senior Vice President, Head of Manufacturing Division)
(3) Departing Executive Officers (effective November 30, 2024)
- Yoshiharu Ikeda (currently Managing Executive Officer)
- Hiroyuki Baba (currently Managing Executive Officer)
- Naoki Noguchi (currently Executive Officer)
(4) Changes in the Positions Assumed by Executive Officers (effective December 1, 2024)
| Position as of December 1, 2024 | Current position | Name |
|---|---|---|
| Representative Director, Executive Vice President Global Corporate Strategy; Global Finance; Legal & Compliance; Intellectual Property; Human Resources; External Affairs; Corporate Governance; IT Management & Data Analytics Administration |
Representative Director, Executive Vice President Global Corporate Strategy; Corporate Governance; Human Resources; Global Finance Administration |
Motoyuki Sakai |
| Member, Board of Directors, Executive Officer President and CEO, Sumitomo Pharma America, Inc. North America Business |
Member, Board of Directors, Executive Officer President and CEO, Sumitomo Pharma America, Inc. |
Tsutomu Nakagawa |
| Managing Executive Officer Business Development & Management Vice President, Head of Business Development & Management Asia Business |
Managing Executive Officer Business Development & Management Vice President, Head of Business Development & Management |
Shigeyuki Nishinaka |
| Managing Executive Officer Supply Chain Division Senior Vice President, Head of Supply Chain Division Head of Japan Business Unit |
Managing Executive Officer Technology Research & Development Division; Manufacturing Division Deputy Head of Japan Business Unit |
Hideyuki Harada |
| Managing Executive Officer Legal & Compliance; Intellectual Property; Human Resources; External Affairs; Corporate Governance; IT Management & Data Analytics |
Managing Executive Officer External Affairs; Corporate Secretariat; Human Resources |
Atsuko Higuchi |
| Managing Executive Officer Research and Development Division Senior Vice President, Head of Research and Development Division Chief Development Officer, Sumitomo Pharma America, Inc. |
Executive Officer Drug Development Division Senior Vice President, Head of Drug Development Division Chief Development Officer, Sumitomo Pharma America, Inc. |
Yumi Sato |
| Executive Officer Corporate Regulatory Compliance & Quality Assurance Division Senior Vice President, Head of Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Executive Officer Regulatory Affairs; Medical Science; Corporate Regulatory Compliance & Quality Assurance Senior Vice President, Head of Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Koichi Kozuki |
| Executive Officer Senior Vice President, Deputy Head of Research and Development Division (Drug Discovery Research) |
Executive Officer Senior Vice President, Head of Drug Research Division Senior Executive Research Director |
Isao Shimizu |
| Executive Officer Senior Vice President, Deputy Head of Research and Development Division (CMC) |
Executive Officer Senior Vice President, Head of Technology Research & Development Division |
Kenji Ueno |
| Executive Officer Sales & Marketing Division Senior Vice President, Head of Sales & Marketing Division Deputy Head of Japan Business Unit |
Sales & Marketing Division Senior Vice President, Head of Sales & Marketing Division Deputy Head of Japan Business Unit |
Koji Yamazaki |
| Executive Officer Legal & Compliance; Intellectual Property; Human Resources |
Senior Vice President, Head of Manufacturing Division Deputy Head of Japan Business Unit |
Kimihiro Mizuno |
Ⅲ. Changes in Personnel (effective December 1, 2024)
Corporate Departments
| Position as of December 1, 2024 | Current position | Name |
|---|---|---|
| Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant; External Affairs; Corporate Governance; IT Management & Data Analytics Vice President, Head of External Affairs Vice President, Head of Regenerative & Cellular Medicine Office |
Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant Vice President, Head of Regenerative & Cellular Medicine Office |
Tomokazu Nagano |
| Vice President, Head of Legal & Compliance | Senior Director, Group I, Legal Affairs | Kazuhisa Kitazawa |
| Vice President, Head of Intellectual Property | Senior Director, Group II, Intellectual Property | Kazuo Eiho |
| Vice President, Head of Human Resources | Vice President, Head of Personnel Development | Tomoko Nakagawa |
| Vice President, Head of IT Management & Data Analytics | Vice President, Head of Global Data Design Office | Satoru Tsuchiya |
Corporate Regulatory Compliance & Quality Assurance (Division)
| Position as of December 1, 2024 | Current position | Name |
|---|---|---|
| Vice President, Head of Regulatory Compliance & Quality Assurance Management (in Japanese language only) | Vice President, Head of Regulatory Compliance & Quality Assurance Management | Kaori Kato |
| Vice President, Head of Quality Management | Vice President, Head of Oita Plant | Toyohiro Nishikawa |
Research and Development (Division)
| Position as of December 1, 2024 | Current position | Name |
|---|---|---|
| Senior Vice President, Deputy Head of Research and Development Division (Project Planning and Promotion) | Senior Research Project Director, Late-phase Drug Research |
Taro Kato |
| Vice President, Project Director, CNS Drug Discovery | Vice President, Head of, Pharmacology Research Unit Senior Director, Pharmacology Group Ⅳ, Pharmacology Research Unit |
Mitsugu Yamanaka |
| Vice President, CMC Program Director |
Senior Director, CMC Planning & Management Group, Technology Research & Development Management | Shohei Horiuchi |
| Vice President, Head of R&D Strategy and Planning | Vice President, Head of Research Planning & Coordination Senior Director, Research Intelligence Group, Research Planning & Coordination |
Masakuni Horiguchi |
| Vice President, Head of R&D Management | Vice President, Head of Development Planning & Management Senior Director, Program Management Group, Development Planning & Management |
Katsunori Maruta |
| Vice President, Head of CNS Drug Discovery Research Unit | Executive Research Director, Drug Research Division | Takeo Ishiyama |
| Vice President, Head of Cancer Drug Discovery Research Unit | Vice President, Head of Modality Research Unit Vice President, Head of Cancer Research Unit |
Hitoshi Ban |
| Vice President, Head of Chemistry Research Unit | Vice President, Head of Chemistry Research Unit Senior Director, Medicinal Chemistry Group II, Chemistry Research Unit |
Katsunori Tsuboi |
| Vice President, Head of Preclinical Research Unit | Vice President, Head of Preclinical Research Unit Senior Director, Toxicology Group II, Preclinical Research Unit |
Izuru Miyawaki |
| Vice President, Head of Drug Discovery Digital Innovation Unit | Senior Research Project Director, Early-phase Drug Research |
Hidetaka Nagata |
| Vice President, Head of Process R&D Unit | Vice President, Head of Process Research & Development Laboratories Senior Director, New Modality Group, Process Research & Development Laboratories |
Nobuhisa Fukuda |
| Vice President, Head of Formulation R&D Unit | Vice President, Head of Formulation Research & Development Laboratories | Makiko Yanagida |
| Vice President, Head of Analytical R&D Unit | Senior Director, Drug Development Analytical Research Group, Analytical Research & Development Laboratories | Yoshiaki Takai |
| Vice President, Head of Medical Affairs | Vice President, Head of Medical Science | Keiko Hirano |
Sales & Marketing (Division)
| Position as of December 1, 2024 | Current position | Name |
|---|---|---|
| Vice President, Head of Sales & Marketing Management | Vice President, Head of Yokohama Branch | Yasuhiro Kami |
| Vice President, Head of Product Marketing | Vice President, Head of Sales & Marketing Management | Yasutoshi Araki |
| Vice President, Head of Distribution Policy Management | Vice President, Head of Distribution Management | Manabu Tatsukawa |
| Vice President, Head of Hokkaido-Tohoku Branch | Vice President, Head of Sapporo Branch Senior Director, Wholesaler Service Group, Sapporo Branch |
Toshinori Kanata |
| Vice President, Head of Kanto-Koshinetsu Branch | Vice President, Head of Kita-Kanto-Koshinetsu Branch | Hiroshi Ogawa |
| Vice President, Head of Shutoken Branch | Vice President, Head of Tokyo Branch | Katsuhiko Nishida |
| Vice President, Head of Tokai-Hokuriku Branch | Vice President, Head of Tokai Branch Senior Director, Wholesaler Service Group, Tokai Branch | Satsuki Otani |
| Vice President, Head of Kansai Branch | Vice President, Head of Product Marketing | Yoshihiro Ariyama |
| Vice President, Head of Chugoku-Shikoku Branch | Vice President, Head of CNS Product Marketing Senior Director, CNS Product Group II, CNS Product Marketing |
Masashi Kimura |
Supply Chain (Division)
| Position as of December 1, 2024 | Current position | Name |
|---|---|---|
| Vice President, Head of Supply Chain Management Senior Director, Strategic Supply Chain Planning Group, Supply Chain Management |
Vice President, Head of Administration, Suzuka Plant | Tetsuya Yamaji |
| Vice President, Head of Manufacturing Technology | Senior Director, Formulation Technology Group, Manufacturing Technology | Takayuki Murakami |
| Vice President, Head of Suzuka Plant | Vice President, Head of Manufacturing Technology Senior Director, Packaging Technology Group, Manufacturing Technology |
Takahiro Jikihara |
| Vice President, Head of Administration, Suzuka Plant | Senior Director, Procurement Management Group, Manufacturing Management | Hirokuni Nakanishi |
| Vice President, Head of Manufacturing Department, Suzuka Plant | Vice President, Head of Manufacturing Department I, Suzuka Plant | Satoshi Nakao |
| Vice President, Head of Engineering, Suzuka Plant Senior Director, Maintenance Group, Engineering, Suzuka Plant |
Senior Director, Maintenance Group, Engineering, Suzuka Plant | Junichi Muto |
| Vice President, Head of Oita Plant | Vice President, Head of Quality Assurance, Oita Plant Senior Director, Quality Assurance Group, Quality Assurance, Oita Plant |
Toshiyuki Hosokawa |
| Vice President, Head of Quality Assurance, Oita Plant Senior Director, Quality Assurance Group, Quality Assurance, Oita Plant |
Senior Director, Quality Assurance Group II, Quality Management | Yasuo Takizawa |
Inquiries from the Press